Leukemia & lymphomaHumansLeukemiaMyeloidAcuteMale
Reduced burden of infection with consecutive day dosing of high dose cytarabine consolidation versus conventional dosing for acute myeloid leukemia.
Alice J Liu, Emily Batterham, Rithin Nedumannil, David Ritchie, Andrew H Wei, Ashish Bajel, Monica A Slavin, Michelle K Yong
Published: 202610.1080/10428194.2025.2599991
Abstract
High-dose cytarabine given on days 1, 3, and 5 (HDAC-135) is a mainstay of consolidation treatment for acute myeloid leukemia (AML). Recent evidence indicates that consecutive daily dosing (HDAC-123) accelerates hematologic recovery and reduces hospi…
Preview only. Read the full abstract at the source